Simplified Chinese
First Public Disclosure of the Environmental Impact Assessment for the Phase I Project of Minhai Biotechnology’s International Vaccine Industrial Base
Release date:
2019-01-25
Author:
Source:
Abstract
(1) Project Name: Minhai Biologics Internationalization Industrial Base for Novel Vaccines (Phase I) Project
(II) Site Selection: Daxing Biopharmaceutical Industry Base, Zhongguancun Science Park, Daxing District, Beijing 053-039 、040、043、044 The parcel is bounded by Tianfu Avenue to the east, the planned land-use boundary to the south, Xiangrui Avenue to the west, and Simiao Road to the north.
(3) Project Scope: Project Land Area 90013.218m2 , the scale of above-ground buildings 135020m2 ; Floor Area Ratio 1.5 ; Building density 40% ; Green space ratio 15% ; Control altitude 36 m. Annual production of adsorbed acellular diphtheria–tetanus–pertussis, inactivated poliovirus, and… b Haemophilus influenzae type b conjugate vaccine 2000 Ten doses; pneumococcal conjugate vaccine 2500 Ten doses; MMRV vaccine series: live attenuated combined measles–mumps–rubella–varicella vaccine 2000 Ten-dose, live attenuated combined measles-mumps-rubella-varicella vaccine 500 Ten doses of freeze-dried live attenuated varicella vaccine 1000 Ten thousand doses.
(4) Name of the Construction Entity: Beijing Minhai Biotechnology Co., Ltd.
Contact: Xia Zhanxiong
Contact phone number: 010-59613634
Email: xiazhanxiong@biominhai.com
(5) Environmental Impact Assessment Report Preparation Unit: Puhua Holdings Co., Ltd.
(6) Online link to the public comment form: http://www.biominhai.com/xwzx_xi/newsId=347.html
(7) Methods and channels for submitting public comments.
Phone: 010-59613634
Email: xiazhanxiong@biominhai.com
During the preparation of the draft environmental impact assessment report, the public may submit comments related to the environmental impact assessment to the project proponent.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09